Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of ESG206 in primary immune thrombocytopenia
CTR20263975Phase 2Active
- Sponsor
- Affinity Biopharma
- Start
- Oct 2026
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ESG206 in immune thrombocytopenia (ITP), sponsored by Affinity Biopharma. Started Oct 2026; status: active.
02
Drugs
ESG206
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on CTR20263975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263975.